A Sympathetic Treatment for Obesity

Jung Dae Kim; Sabrina Diano

doi:10.1016/j.cmet.2020.05.009

A Sympathetic Treatment for Obesity

Cell Metab. 2020 Jun 2;31(6):1043-1045. doi: 10.1016/j.cmet.2020.05.009.

Authors

Jung Dae Kim¹, Sabrina Diano²

Affiliations

¹ Program in Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT 06520, USA; Departments of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA.
² Program in Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT 06520, USA; Departments of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: sabrina.diano@yale.edu.

Abstract

Amphetamine (AMPH), mainly used in the treatment of attention deficit hyperactivity disorder and narcolepsy, has weight loss properties, although with detrimental cardiovascular effects. In this issue, Mahú et al. (2020) describe the effect of a new derivative of AMPH, "PEGyAMPH," a brain-spared anti-obesity drug that alters sympathetic activity without cardiovascular side effects.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Amphetamine / therapeutic use
Attention Deficit Disorder with Hyperactivity* / drug therapy
Brain
Central Nervous System Stimulants* / therapeutic use
Humans
Obesity / drug therapy

Substances

Central Nervous System Stimulants
Amphetamine

Abstract

Publication types

MeSH terms

Substances

Grants and funding